Alyeska Investment Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Alyeska Investment Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-52,500	Closed	-$6.22M	–	702
2022 Q1	$6.22M	Buy	+52,500	New	+$6.55M	0.07%	263
2021 Q4	–	Sell	-60,954	Closed	-$8.47M	–	822
2021 Q3	$8.47M	Buy	+60,954	New	+$7.61M	0.1%	225
2020 Q1	–	Sell	-60,934	Closed	-$3.32M	–	543
2019 Q4	$3.32M	Buy	60,934 +10,233	+20%	+$507K	0.04%	252
2019 Q3	$2.12M	Sell	50,701 -144,545	-74%	-$6.11M	0.03%	285
2019 Q2	$8.55M	Buy	+195,246	New	+$11M	0.11%	183
2017 Q3	–	Sell	-149,651	Closed	-$3.74M	–	602
2017 Q2	$3.74M	Buy	+149,651	New	+$3.45M	0.03%	305

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's BHVN Position: Q2 2022 in Review

Alyeska Investment Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 52,500 shares — an estimated $6.22M sold.

Alyeska Investment Group first reported a position in BHVN in Q2 2017 and held it in 6 quarters. The position peaked at $8.55M in Q2 2019. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Alyeska Investment Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Alyeska Investment Group sold 52,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $6.22M.
Alyeska Investment Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 6 quarters.
Alyeska Investment Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $8.55M in Q2 2019.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Alyeska Investment Group's 13F filing for Q2 2022, filed 15 Aug 2022.